Sunesis Pharmaceuticals, Inc. News Releases http://ir.sunesis.com/ Sunesis Pharmaceuticals, Inc. News Releases en Sunesis Pharmaceuticals Reports First Quarter 2019 Financial Results and Recent Highlights http://ir.sunesis.com/news-releases/news-release-details/sunesis-pharmaceuticals-reports-first-quarter-2019-financial Phase 1b/2 Trial of Vecabrutinib Advances into 200 mg Cohort Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the first quarter ended March Wed, 08 May 2019 16:05:00 -0400 Sunesis Pharmaceuticals, Inc. News Releases 15496 Sunesis Pharmaceuticals to Host Conference Call on May 8th to Discuss First Quarter 2019 Financial Results and Recent Highlights http://ir.sunesis.com/news-releases/news-release-details/sunesis-pharmaceuticals-host-conference-call-may-8th-discuss-0 SOUTH SAN FRANCISCO, Calif. , May 01, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Wednesday, May 8 th , 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended Wed, 01 May 2019 07:00:00 -0400 Sunesis Pharmaceuticals, Inc. News Releases 15491 Sunesis Pharmaceuticals Announces Refinancing of Existing Loan with $5.5 Million Loan from Silicon Valley Bank http://ir.sunesis.com/news-releases/news-release-details/sunesis-pharmaceuticals-announces-refinancing-existing-loan-55 SOUTH SAN FRANCISCO, Calif. , April 29, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has entered into a $5.5 million loan agreement with Silicon Valley Bank . The new agreement allows the company to retire its existing loan and defer any principal Mon, 29 Apr 2019 16:05:00 -0400 Sunesis Pharmaceuticals, Inc. News Releases 15481 Sunesis Pharmaceuticals to Present at 18th Annual Needham & Company Healthcare Conference http://ir.sunesis.com/news-releases/news-release-details/sunesis-pharmaceuticals-present-18th-annual-needham-company SOUTH SAN FRANCISCO, Calif. , April 03, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn , Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the Needham & Company 18 th Annual Wed, 03 Apr 2019 07:00:00 -0400 Sunesis Pharmaceuticals, Inc. News Releases 15456 Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights http://ir.sunesis.com/news-releases/news-release-details/sunesis-pharmaceuticals-reports-fourth-quarter-and-full-year-12 Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , March 07, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the fourth quarter and year ended December 31, 2018 . Thu, 07 Mar 2019 16:01:00 -0500 Sunesis Pharmaceuticals, Inc. News Releases 15406 Sunesis Pharmaceuticals to Participate in Upcoming Investor Conferences http://ir.sunesis.com/news-releases/news-release-details/sunesis-pharmaceuticals-participate-upcoming-investor SOUTH SAN FRANCISCO, Calif. , March 04, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will participate in three upcoming investor conferences in March: Event: Cowen and Company 39 th Annual Health Care Conference Date: Monday, March 11 th Mon, 04 Mar 2019 07:00:00 -0500 Sunesis Pharmaceuticals, Inc. News Releases 15386 Sunesis Pharmaceuticals to Host Conference Call on March 7th to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights http://ir.sunesis.com/news-releases/news-release-details/sunesis-pharmaceuticals-host-conference-call-march-7th-discuss SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Thursday, March 7 th , 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and Thu, 28 Feb 2019 07:00:00 -0500 Sunesis Pharmaceuticals, Inc. News Releases 15376 Sunesis Announces Pricing of $20 Million Offering of Securities http://ir.sunesis.com/news-releases/news-release-details/sunesis-announces-pricing-20-million-offering-securities-1 SOUTH SAN FRANCISCO, Calif. , Jan. 17, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the pricing of underwritten public offerings of (i) 23,000,000 shares of its common stock and (ii) 17,000 shares of its non-voting Series E Convertible Preferred Stock Thu, 17 Jan 2019 21:58:00 -0500 Sunesis Pharmaceuticals, Inc. News Releases 15306 Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock http://ir.sunesis.com/news-releases/news-release-details/sunesis-announces-proposed-public-offering-common-stock-and-1 SOUTH SAN FRANCISCO, Calif. , Jan. 17, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series E Convertible Preferred Stock in underwritten public Thu, 17 Jan 2019 16:05:00 -0500 Sunesis Pharmaceuticals, Inc. News Releases 15291 Sunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies http://ir.sunesis.com/news-releases/news-release-details/sunesis-pharmaceuticals-announces-advancement-100mg-cohort-phase - 50 mg Cohort Completed - - Clinical Update Expected in the Second Quarter of 2019 - SOUTH SAN FRANCISCO, Calif. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company has opened the 100 mg cohort in the Phase 1b/2 trial of its non-covalent Wed, 02 Jan 2019 07:00:00 -0500 Sunesis Pharmaceuticals, Inc. News Releases 15261